PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Randox Laboratories Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Randox Introduces Practical Solutions for Translational Science - The sole purpose of translational science is to transfer scientific discoveries made in ‘basic research’ to clinical reality, to improve the health of individuals and reduce suffering - RandoxPharmaServices.com
Randox Introduces Practical Solutions for Translational Science

 

NewswireToday - /newswire/ - Crumlin, Antrim, United Kingdom, 2011/05/23 - The sole purpose of translational science is to transfer scientific discoveries made in ‘basic research’ to clinical reality, to improve the health of individuals and reduce suffering - RandoxPharmaServices.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Randox Pharma Services was founded with such a translational mission, and for 30 years has been carrying out R&D, custom assay development and supplying diagnostic solutions; all underpinned by a strong commitment to collaborate with leading academic research centres and pharmaceutical companies globally.

In recognition of the vital role biomarkers play in translational medicine, Randox Pharma Services supply an unrivalled range of single analyte and multiplex diagnostic kits direct to end user laboratories. Indeed, even kits produced primarily for research come under the same scrutiny as any commercial IVD assay i.e. imprecision less than 10%, fully optimised to eliminate cross-reactivity and non-specific binding to name just a few of our stringent QA processes.

As a private company Randox Pharma Services can be flexible and are swift to focus our significant in-house resources and expertise towards any pressing healthcare need; with a particular focus on oncology, infectious disease and metabolic disorders.

To enable this Randox have developed Biochip Array Technology, a multiplex technology which allows the simultaneous detection of multiple biomarkers from a single patient sample. Given the increased value of multiple biomarkers to improve patient diagnosis, such a technology is the ideal ‘target platform’ for translational science. Already arrays have been developed which are applicable to a broad range of therapeutic areas, with applications including multiplex immunoassays and nucleic acid based SNP, mutation, gene expression and pathogen detection arrays.

Randox Pharma Services (randoxpharmaservices.com) also offer over 130 enzymatic, substrate and immunoturbidimetric assays on our class-leading range of RX Series chemistry analysers which provide quality results at every phase from pre-clinical testing through to the clinic.

With robust, fit-for-purpose assays a pre-requisite for research, biomarker validation and ultimately translational science, only an established clinical diagnostic company such as Randox has the scientific and regulatory experience required. All to meet the pressing need for the more rapid translation of novel biomarkers to clinical utility.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Randox Laboratories Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Randox Introduces Practical Solutions for Translational Science

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Charlotte Jess - Randox.com 
+44(0)28 4245 7832 pharmaservices[.]randox.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Randox Laboratories Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Randox Laboratories Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)